Podcasts about zepbound

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have reshaped the weight-loss landscape almost overnight — but the way they're often prescribed leaves people under-fueled, losing muscle, and going it alone. In this episode of The Coaching Lab, host Leigh Baker sits down with National Board Certified Health & Wellness Coach Erin Chain and triple-board-certified physician Dr. Sheri Poznanovic of Optin Health & Nutrition to unpack what's really happening in the GLP-1 era — and where health and wellness coaching fits into the care plan.Together they explore why so many people on GLP-1s aren't eating or hydrating enough, how rapid weight loss can mask dangerous muscle mass loss, and why a "prescribe-and-disappear" model falls short. Dr. Poznanovic explains the multidisciplinary approach the Obesity Medicine Association recommends — combining medication, nutrition, body composition testing, VO2 max assessment, and coaching — while Erin shares real-world stories of clients navigating low energy, food noise, protein gaps, medication interactions, and the stigma of being on a GLP-1.Whether you're a coach, a clinician, an employer weighing GLP-1 coverage, or someone considering these medications yourself, this conversation offers a grounded, human look at doing weight loss in a way that protects strength, health span, and quality of life — not just the number on the scale.In this episode: • Why coaching alongside a GLP-1 changes outcomes • The under-eating and muscle-loss risks no one warns you about • Protein targets, carbs, and why "anti-carb" advice backfires • Body composition and VO2 max testing in weight management • Medication interactions as you lose weight • Navigating stigma and the joy of food • What employers and coaches should know before adding GLP-1sCoaches: Explore CE credits at catalystcoachinginstitute.com Employers: Learn about Catalyst Coaching's GLP-Whole offering — results@catalystcoaching360.com Join us this fall at the Rocky Mountain Coaching Retreat & Symposium: catalystcoachinginstitute.com/retreatInfo re earning your health & wellness coaching certification, annual Rocky Mountain Coaching Retreat & Symposium & more via https://www.catalystcoachinginstitute.com/ Best-in-class coaching for Employers, EAPs & wellness providers https://catalystcoaching360.com/Tap into the home of the (freely available) Not Done Yet! articles on unlocking life's 2nd half here.YouTube Coaching Channel https://www.youtube.com/c/CoachingChannelContact us: Results@CatalystCoaching360.comTwitter: @Catalyst2ThriveWebsite: CatalystCoaching360.comIf you are a current or future health & wellness coach, please check out our Health & Wellness Coaching Community on Facebook: https://www.facebook.com/groups/278207545599218.  This is a wonderful group if you are looking for encouragement, ideas, resources and more. 

Is gaining weight really the worst thing that can happen?Obviously, there are a million worse things. But for me, the answer is still kind of yes—and not because of the number on the scale.At my highest weight, the biggest loss wasn't clothing size or how I looked. It was my quality of life. My anxiety got worse. I dealt with agoraphobia and depression. I avoided things, sat on the sidelines, and slowly made my world smaller.After gaining a few pounds back this summer, I had a wake-up call. I'm nowhere near where I was, but I also know I never want to go back to living that way.This episode is about what weight gain can quietly take from you—and why I'm choosing to stop that slide now.Irresistible Links:Show Notes

You cannot open your phone anymore without hearing about Ozempic, Wegovy, Mounjaro, Zepbound, retatrutide, and before-and-after transformations. One person says GLP-1s are the greatest thing ever. Another says they are going to destroy your health. As usual, the truth is somewhere in the middle. In this episode, I break down GLP-1s specifically through the lens of perimenopause and menopause, because midlife women are dealing with a completely different metabolic landscape. Estrogen is changing. Muscle is easier to lose. Insulin sensitivity may be shifting. Sleep is falling apart. Belly fat is showing up where it never used to. And simply telling a woman to eat less and exercise more is not a strategy. We talk about where GLP-1s can be incredibly useful, why HRT and GLP-1s are not interchangeable, and why protecting muscle has to be one of your top priorities if you are using these medications. I also get into dosing, microdosing, appetite suppression, thyroid and hormone optimization, realistic weight-loss rates, and why the goal should never be to get as skinny as possible as fast as possible. The goal is to lose fat while preserving muscle, supporting hormones, improving metabolic health, and having an actual plan for what happens after the weight comes off. In this episode, we cover: Why menopause changes fat distribution and increases abdominal fat for many women How declining estrogen, muscle loss, sleep, and insulin resistance affect midlife weight How GLP-1 medications work beyond simple appetite suppression Why GLP-1s are not "cheating" Why GLP-1 therapy does not replace HRT Whether HRT and GLP-1s can be used together Why muscle loss is one of the biggest concerns with GLP-1 use Why protein and resistance training matter so much Why having no appetite does not mean your dose is perfect Microdosing versus standard GLP-1 dosing Why increasing your dose too quickly can backfire What a realistic rate of weight loss can look like The importance of thyroid and hormone optimization when weight loss stalls Why maintenance needs to be part of the plan from day one Who This Episode Is For This episode is for women in perimenopause and menopause who are considering a GLP-1, already taking one, or wondering whether these medications could help with stubborn midlife weight gain. It is especially for women who want to lose fat without sacrificing muscle, energy, hormones, bone health, or long-term metabolic health. If you are confused by the microdosing hype, worried about muscle loss, unsure whether you should do HRT or a GLP-1 first, or wondering why your weight loss has stalled even though you are taking medication, this episode is for you.     Sponsors BEAM: Use coupon code HORMONE for 20% off your order Try the power of copper peptides on your skin today and get 20% off your order with coupon code km20 here.     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are everywhere right now. Maybe you're curious about them. Maybe you're already taking one. Or maybe part of you feels like using medication would somehow be "cheating." In this episode, Dara takes a step back from the debate and looks at the bigger picture. What do GLP-1 medications actually do? Can they reduce food noise? And if they quiet your desire for food, does that mean they've resolved the reason you were turning to food in the first place? Dara shares research and perspectives from several medical and psychological professionals, including differing opinions about who may benefit most from GLP-1 medications, what happens when the medication is stopped, and how appetite suppression could potentially interact with perfectionism and rigid thinking. But this isn't a yes-or-no episode about whether you should take a GLP-1. Instead, Dara wants you to ask better questions. If the food noise disappeared tomorrow, would the rest of your life feel resolved? What would you finally believe about yourself if you reached your goal weight? And why does that belief have to wait until you lose the weight? Dara also explores the connection between emotional eating, food noise, over-hunger, and over-desire—and why understanding the why behind your eating patterns may be just as important as changing the behavior itself. In this episode, you'll learn: What GLP-1 medications actually do to appetite and food noise Why quieting food noise isn't necessarily the same as resolving its underlying cause Why doctors and researchers don't all agree about GLP-1 medications How emotional eating can be connected to suppressing or avoiding difficult emotions The difference between over-hunger and over-desire How perfectionism and all-or-nothing thinking may factor into your relationship with food The questions to ask yourself before deciding whether a GLP-1 is right for you Important: This episode is for education and personal reflection, not medical advice. Talk with your healthcare provider about whether a GLP-1 medication is appropriate for you. If you're considering a GLP-1—or you're already taking one and still wondering what's really driving your relationship with food—Dara invites you to book a free diagnosis call to explore your unique pattern. Book your call HERE. Subscribe for more episodes on emotional eating!

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks down two of the biggest GLP-1 stories of the week: why most states are opting out of the Trump administration's new Medicaid obesity-drug coverage model, and why employers are preparing to cut GLP-1 coverage in 2027.We also dig into the growing conversation around GLP-1 microdosing after Real Housewives of Orange County star Emily Simpson described using a lower-frequency maintenance strategy after losing around 50 pounds. Could lower-dose or intermittent GLP-1 therapy eventually become a legitimate maintenance tool? Could it help lower long-term healthcare costs? And could earlier, lower-intensity treatment eventually become a form of prophylaxis against obesity-related disease?This episode covers Medicaid GLP-1 coverage, the BALANCE model, Zepbound coverage, Wegovy coverage, employer insurance changes, compounded GLP-1 access, GLP-1 microdosing, obesity maintenance, semaglutide, tirzepatide, metabolic disease prevention, obesity medicine, healthcare costs, and the future of GLP-1 treatment.If you take Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, compounded tirzepatide, or simply follow the rapidly changing world of obesity medicine, this is a conversation you need to hear.Subscribe to On The Pen for breaking GLP-1 news, obesity medicine updates, access and insurance coverage news, new weight-loss drugs, clinical research, and patient advocacy.More from On The Pen: https://linktr.ee/manonthemounjaro#GLP1 #Ozempic #Wegovy #Mounjaro #Zepbound #Semaglutide #Tirzepatide #Microdosing #ObesityMedicine #WeightLoss #Medicaid #HealthInsurance #CompoundedGLP1 #Obesity #GLP1News

Ralph in Virigina called Mark to tell him about how Zepbound was the best weight-loss drug that he took. Tony in Old Bridge, NJ, called in to talk about how Data Centers going underground may be a possibility.

Oil Reserves taking a hit. Finally getting to the recent high profile earnings. Market Top Calls (again). ALL TIME HIGHS – Then some consolidation (then highs again). Situational Awareness Update. SpaceX Bounces… PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); Follow John S. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Oil Reserves taking a hit - Getting to the recent high profile earnings - Market Top Calls (again) Markets - ALL TIME HIGHS - Then some consolidation - Lets round out earnings - Situational Awareness Update - SpaceX Bounces... Etsy - Layoffs With Better Numbers - Etsy is cutting about 220 jobs, or 12% of its workforce. - Management said the cuts were not primarily about cost savings or AI. ----- CEO Kruti Patel Goyal stated the restructuring aims to simplify the organization, remove management layers, and speed up decision-making to better compete against massive rivals like Amazon, Temu, and TikTok Shop - Q2 revenue was about $668 million and core marketplace sales improved. - Etsy also authorized another $2 billion share buyback. - Comes after selling Depop to eBay for about $1.4 billion. Polysilicon - Tariffs Plus Price Floors - U.S. policy adds a 15% tariff and minimum import prices on polysilicon and solar products. - Goal is to protect domestic production from low-cost foreign competition. - U.S. share of global polysilicon capacity fell from about 50% in 2005 to under 2% in 2024. - First Solar and T1 Energy jumped on the announcement. ---- The same playbook - rinse and repeat Chipotle - Salmonella Returns - Minnesota officials linked a salmonella outbreak to jalapenos served at Chipotle. - Chipotle removed the affected pepper supply and switched growers. - Shares fell roughly 8%-10% as investors remembered the company's earlier food-safety problems. - This is on top of the lettuce situation with Sweetgreen- look at  STOCK CHART FOR SG Michael Burry - Calling a Major Top - Michael Burry says the market may be near a "major top." - Warned of the possibility of a 1987-style market drop. - He is short names including Nvidia, Palantir, Tesla and semiconductor stocks. - Main concern is stretched valuations and crowded trades unwinding quickly. - This may be the 100th top he has called since the GFC ---- NVIDIA TURNS GPUs INTO AN ASSET CLASS - Nvidia signed preliminary agreements with Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR to mobilize more than $500 billion for AI infrastructure. - The Wall Street firms would create dedicated pools of capital to finance Nvidia-based data centers and compute infrastructure at what Nvidia calls attractive rates for customers. - Jensen Huang: “This is really the first time that technology chips have become an investable asset class.” Nvidia says the compute assets now generate revenue and can increasingly be financed like infrastructure. - Nvidia could backstop as much as 25% of individual investments on a case-by-case basis - potentially up to about $125 billion if applied across the full program. STRATEGIC PETROLEUM RESERVE BREAKS 300 MILLION - The Strategic Petroleum Reserve fell by 6.1 million barrels to 298.7 million barrels for the week ended Aug. 7 - below 300 million for the first time since January 1983. - The SPR started 2026 around 415 million barrels, meaning more than 100 million barrels have already come out this year as releases were used to offset disruptions from the Iran conflict. - The reserve's authorized storage capacity is roughly 714 million barrels, leaving current inventories at about 42% of capacity. - Oil on the rise last week Earnings and such Toyota - Big Buyback, Better Outlook - Toyota raised its annual operating-profit forecast 13%, helped by the weaker yen. - Announced a share buyback worth up to $6.3 billion. - Quarterly operating profit still fell 9%, hurt by China weakness and higher Middle East-related costs. McDonald's - Value Problem - U.S. same-store sales rose just 0.8%, below expectations and well below last year's 2.5% growth. - Management blamed weak execution of value promotions and fewer digital deals. (and probably because everyone is taking weight loss drugs - see above) - Lower-income customer traffic remains a major pressure point. - McDonald's is bringing back more digital offers and loyalty promotions to drive traffic. Eli Lilly - Weight-Loss Machine - Lilly crushed Q2 expectations as Mounjaro and Zepbound drove most of the growth. - Mounjaro sales hit $9.94 billion; Zepbound brought in $4.93 billion. - Raised 2026 revenue guidance to $85-$87 billion. - Verzenio, its major breast-cancer drug, remains one of Lilly's biggest non-obesity products. - Lilly continues widening its lead over Novo Nordisk in the obesity-drug market. Disney - Parks Keep Printing Money - Quarterly adjusted EPS rose 28% to $2.06, beating the $1.86 estimate. - Parks and experiences revenue increased 10% to nearly $10 billion. - Global park attendance grew 4%. - Disney is selling its 50% stake in A+E Networks to Hearst for an estimated $1.2 billion. Oil - OPEC Adds Barrels, Maybe - OPEC+ agreed to raise September production targets by another 188,000 barrels per day. - The increase completes the rollback of a 1.65 million-barrel-per-day supply cut dating back to 2023. (In other words - planned so not a surprise) - Actual supply remains constrained because several producers are already pumping below quota. - Any normalization around the Strait of Hormuz could suddenly make OPEC+'s additional barrels much more important. Berkshire Hathaway - Greg Abel Starts Spending - Q2 operating earnings rose 16% to about $13 billion. - Berkshire bought $23.5 billion of stocks and sold just $3.7 billion - its first quarter as a net stock buyer in 14 quarters. - Bought back $4.5 billion of Berkshire shares, versus only $235 million in Q1. - Cash dropped from roughly $380 billion to $365 billion as Abel starts putting the massive cash pile to work. - Important shift: Buffett is still chairman, but this is one of the clearest signs yet of how Greg Abel may allocate capital differently as CEO. Situational Awareness - Nearly Blows Up, Investors Want Back In - The fund lost 67% in July after leveraged AI bets collapsed and forced a major stock sale to Citadel. - Despite the blowup, Situational Awareness was still up about 80% for 2026 because of huge earlier gains. - Bloomberg says Silicon Valley investors are already asking to put more money into the fund. - Situational Awareness is currently telling prospective investors it is not accepting new capital. - The fund has also continued making large private investments even after the near-collapse. --- Most recent was a $400B ---- There is some talk that Citadel made out like a bandit on the rescue Mercedes AMG - The Car Literally Brands You - Two Mercedes AMG owners filed a class-action lawsuit claiming the metal AMG logo embedded in the seat becomes dangerously hot in the sun. - One driver says he suffered first- and second-degree burns, with a dermatologist describing the injury as "AMG inscribed." - The lawsuit wants Mercedes to cover damages and remove the metal logos from affected vehicles. - Hard to beat this one: pay AMG money and get the logo branded into your back. Europe's Drought - History Starts Popping Out - Extreme drought and low river levels are exposing things that have been underwater or hidden for decades or centuries. - In Serbia, sunken German World War II warships have reappeared in the Danube. - In Britain, dry ground revealed outlines of medieval buildings; mammoth remains and ancient structures have also surfaced elsewhere. - Serious drought story, but visually one of the strangest side effects of the summer. Golden Toilet - $6 Million Flush - The 18-carat gold toilet was ripped out of Blenheim Palace in a five-minute raid and has never been recovered - but there is a conviction. - Prosecutors used phone data, forensic evidence and planning activity to link the gang to the theft. - One defendant had cased the palace beforehand and photographed entry points; another man had already pleaded guilty and admitted helping move the stolen gold. - Prosecutors believe the 98-kilo toilet was quickly cut up or melted down and sold as gold. - So the conviction was based on evidence of the robbery and disposal - not on recovering the actual toilet. Final Follow Up SpaceX - Space Junk Smashes Into the Moon - A dead SpaceX Falcon 9 rocket stage crashed into the moon at about 5,400 mph after drifting through space since January 2025. - The roughly 4-ton, school-bus-size object kicked up a lunar dust plume that astronomers detected from Chile. - The impact was accidental - solar activity and gravity gradually pushed the abandoned rocket stage onto a collision course. - NASA and SpaceX are now discussing ways to prevent future lunar crashes as more hardware heads toward the moon. - NEED Space garbage Trucks - something we have discussed on show for years (see next) Space Garbage Trucks - This Is Becoming a Business - Astroscale is building spacecraft designed to inspect, capture and remove dead satellites and other orbital debris. - Its ADRAS-J mission demonstrated close approach and inspection of a large piece of existing space junk - a key step before actually grabbing and removing debris. - ClearSpace is developing similar debris-removal spacecraft, including missions designed to rendezvous with and capture abandoned rocket hardware. - The business model is basically orbital towing: governments and satellite operators pay to remove dangerous junk or service aging spacecraft. - With tens of thousands of tracked objects already in orbit, "space sanitation" could become a real infrastructure business.   Love the Show? Then how about a Donation? PayPal.Donation.Button({ env: 'production', hosted_button_id: 'JJJHP2GDEJC7J', image: { src: 'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt: 'Donate with PayPal button', title: 'PayPal - The safer, easier way to pay online!' } }).render('#donate-button-2'); THE CLOSEST TO THE PIN for SpaceX (SPCX) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!   FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Nancy apologized for making the staff meeting go long yesterday. Karly texted and thanked Joey during the meeting because she thought he was trying to wrap things up so everyone could get on with their day. Joey shared that his mom, Babs, saw his "summer fit" picture and immediately asked if he was taking Zepbound. He said nope, just diet and exercise, which led to a conversation about how common weight loss drugs have become. Nancy said her son refuses to sleep in the guest room during their home renovation because he thinks the antique beds are haunted. The furniture came from her great-grandmother's old hotel, but he's convinced there are ghosts involved and plans to sleep on the couch instead. The show got into the crazy Penn State cocaine ring story involving fraternity members who allegedly had pledges helping package and sell drugs. Joey immediately turned it into a dramatic movie trailer. Joey and Nancy talked about "after-call ads," where certain apps can pop up advertisements the second you hang up a phone call. That turned into a discussion about all the random places ads have invaded, including gas pumps, rideshares, streaming services, and airport security lines. Hot Tea: Hayden Panettiere's mom spoke publicly after Hayden's passing and said she never approved of Hayden's boyfriend. Lainey Wilson landed her first comedy role on Leanne, starring East Tennessee favorite Leanne Morgan. And a man in Norway got fined nearly $7,000 for waking up a sleeping polar bear with a foghorn. Nancy was completely over refrigerator shopping after discovering modern fridges now come with cameras, grocery tracking, talking door alerts, and giant cocktail ice makers. She finally hired an appliance specialist because the choices were overwhelming. The show watched a viral clip of two Detroit TV anchors arguing off-camera and compared it to one of their own awkward radio moments. Joey brought up the time Nancy kept correcting him while he was trying to talk about the Budweiser Clydesdales. Lucky 7 for $50 to Old South Candy Joey admitted he has a weird rule about driving. If he sees someone he knows on the road, he refuses to pass them and tries not to be seen. His nightmare came true when a pastor spotted him at a stoplight flossing his teeth like his life depended on it. The show gave away a chance to ride Dollywood’s new Night Flight Expedition coaster with them. Listeners text FLIGHT to 865-656-9485. Joey and Nancy say 5 people's names on the air. The first of those people to call us wins. What Makes You Special? I'm a Foley Artist! See omnystudio.com/listener for privacy information.

Nancy apologized for making the staff meeting go long yesterday. Karly texted and thanked Joey during the meeting because she thought he was trying to wrap things up so everyone could get on with their day. Joey shared that his mom, Babs, saw his "summer fit" picture and immediately asked if he was taking Zepbound. He said nope, just diet and exercise, which led to a conversation about how common weight loss drugs have become. Nancy said her son refuses to sleep in the guest room during their home renovation because he thinks the antique beds are haunted. The furniture came from her great-grandmother's old hotel, but he's convinced there are ghosts involved and plans to sleep on the couch instead. The show got into the crazy Penn State cocaine ring story involving fraternity members who allegedly had pledges helping package and sell drugs. Joey immediately turned it into a dramatic movie trailer. Joey and Nancy talked about "after-call ads," where certain apps can pop up advertisements the second you hang up a phone call. That turned into a discussion about all the random places ads have invaded, including gas pumps, rideshares, streaming services, and airport security lines. Hot Tea: Hayden Panettiere's mom spoke publicly after Hayden's passing and said she never approved of Hayden's boyfriend. Lainey Wilson landed her first comedy role on Leanne, starring East Tennessee favorite Leanne Morgan. And a man in Norway got fined nearly $7,000 for waking up a sleeping polar bear with a foghorn. Nancy was completely over refrigerator shopping after discovering modern fridges now come with cameras, grocery tracking, talking door alerts, and giant cocktail ice makers. She finally hired an appliance specialist because the choices were overwhelming. The show watched a viral clip of two Detroit TV anchors arguing off-camera and compared it to one of their own awkward radio moments. Joey brought up the time Nancy kept correcting him while he was trying to talk about the Budweiser Clydesdales. Lucky 7 for $50 to Old South Candy Joey admitted he has a weird rule about driving. If he sees someone he knows on the road, he refuses to pass them and tries not to be seen. His nightmare came true when a pastor spotted him at a stoplight flossing his teeth like his life depended on it. The show gave away a chance to ride Dollywood’s new Night Flight Expedition coaster with them. Listeners text FLIGHT to 865-656-9485. Joey and Nancy say 5 people's names on the air. The first of those people to call us wins. What Makes You Special? I'm a Foley Artist! See omnystudio.com/listener for privacy information.

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he's right, it could completely change access to obesity treatment in America.But getting there may depend on something most patients have never heard of: the global peptide manufacturing supply chain.In this episode of The Weekly Dose from On The Pen, Dave Knapp, Man on the Mounjaro, breaks down one of the biggest weeks in GLP-1 and obesity medicine news, including the surprising role of Chinese pharmaceutical manufacturer WuXi AppTec, which Bloomberg described as having a “GLP-1 chokehold” while U.S. policymakers wrestle with reducing America's dependence on Chinese biotechnology.We also dig into one of the strangest GLP-1 stories of the year. Amylyx Pharmaceuticals just reported positive Phase 3 results for avexitide, a GLP-1 receptor antagonist, meaning it actually BLOCKS GLP-1. The drug reduced serious hypoglycemic events by 55% in patients with post-bariatric hypoglycemia, a debilitating condition that can occur after gastric bypass surgery.Then we get personal.Online personality Clavicular recently described becoming apathetic while taking a high dose of retatrutide, renewing the conversation around GLP-1 medications, anhedonia, emotional blunting, dopamine and reward signaling. Dave has firsthand experience with anhedonia during GLP-1 treatment and previously discussed that experience as part of coverage on the Today Show.At what point does turning down food noise start turning down everything else?We also examine Serena Williams' return to professional tennis while openly using Zepbound (tirzepatide) and the growing debate over whether GLP-1 medications could ever be considered performance-enhancing drugs in professional sports.Plus, new research suggests GLP-1 medications and significant weight loss may improve testosterone levels and fertility markers in men with obesity-related low testosterone, raising important questions about metabolic health, hypogonadism and when testosterone replacement therapy may or may not be appropriate.In this episode:

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Do you actually know the difference between a rough night's sleep and a real sleep disorder?Most people use the word "insomnia" for both, but the line between them is a lot more specific than it sounds — and knowing where that line sits can change how someone approaches their own sleep struggles entirely.That's exactly what this episode digs into, with Dr. Muhammad Usama returning to the show after a prior conversation on Zepbound and sleep apnea. He's triple board-certified in sleep and obesity medicine, practices at MultiCare Health System in the greater Seattle area, and serves as an adjunct clinical professor of medicine at A.T. Still University School of Osteopathic Medicine. His clinical and research work centers on the intersection of obstructive sleep apnea, obesity, and cardiometabolic health, with a particular focus on GLP-1 therapies like tirzepatide.This time, the conversation turns to insomnia itself: what actually qualifies as chronic insomnia, why it happens, and what treatment options genuinely move the needle versus which ones just create the illusion of help.Topics discussed:When Does Insomnia Stop Being Normal?The Switch That Turns Short-Term Insomnia Into Chronic InsomniaIs Insomnia Genetic? The Nature vs. Nurture AnswerChronic Insomnia: Why CBT-i, Not Sleep Hygiene, Is the First-Line TreatmentHow to Actually Access CBT-i (No Therapist Couch Required)Do Sleep Medications Actually Work? The Research Says Not MuchAcute Insomnia: How Early Intervention Prevents It From Becoming ChronicDoes Melatonin Actually Help With Sleep? What It's Really ForDo Sleep Supplements Like Magnesium Actually Work?Alcohol and Marijuana for Sleep: Do They Actually Help—or Hurt?Chronic Insomnia: When to Get Evaluated and What Actually WorksInsomnia is far more common, and far more treatable, than most people realize. Between understanding the difference between acute and chronic, recognizing the habits that quietly turn one into the other, and knowing which treatments actually hold up under research, this episode covers a lot of ground that can change how someone approaches their own sleep for good. If sleep has been a struggle for months, it's worth getting evaluated rather than just living with it — this episode is a great place to start.Connect with Dr. Usama:LinkedIn: Muhammad Usama, MD FACP DABOMInstagram: sleepwarriormd  Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

What happens to eating disorder recovery when the culture around you starts celebrating weight loss again? In this deeply personal solo episode, Dr. Marianne continues sharing her eating disorder recovery story and talks about something that has surprised her: the return of body insecurities during the Age of Ozempic. After recovering from a decades-long history of anorexia, binge eating disorder, orthorexia, and bulimia, she rarely spends much time thinking about her body size. But the rise of Ozempic and other GLP-1 medications like Zepbound and Wegovy has changed the cultural conversation around weight, thinness, and fat bodies. During the height of the body diversity movement, living in a larger body felt different. Plus-size clothing became more visible. Larger bodies appeared in advertising. Conversations about weight stigma, fatphobia, body neutrality, and fat liberation entered the mainstream. Now, many of those gains seem to be disappearing as celebrities become smaller, plus-size departments vanish from stores, and thinness once again becomes something we're expected to pursue. When Eating Disorder Recovery Meets the Age of Ozempic Dr. Marianne shares what it's like to encounter old eating disorder and body image thoughts after years of recovery. Sometimes those thoughts arrive unexpectedly: Look at that celebrity. They did it. Why can't I? Having that thought doesn't mean eating disorder recovery has failed. Recovery doesn't necessarily erase decades of conditioning around weight and body size. Instead, it can help us recognize internalized weight bias when it resurfaces and decide whether we want to listen to it. Dr. Marianne also discusses an important distinction: wanting a smaller body isn't necessarily the same thing as wanting relief from anti-fat bias. Sometimes the thought, Life would be easier if I were thinner, reflects a painful reality about how fat people are treated rather than a genuine desire to change one's body. The World Is Getting Smaller for Fat People Anti-fat bias doesn't exist only in our thoughts. It shows up in the physical world. Plus-size clothing departments have disappeared from many stores, forcing people in larger bodies to shop online. Airplane seats continue to create accessibility barriers for larger passengers. Cars, restaurant booths, waiting-room chairs, theaters, and other public spaces frequently fail to accommodate body diversity. The message can become impossible to ignore: if the world won't make more space for you, you're expected to make yourself smaller. Dr. Marianne explores the mental health toll of repeatedly navigating environments that weren't designed for your body. Constantly wondering whether a seat will fit, whether a store carries your size, or whether a healthcare provider will blame your symptoms on weight creates an enormous cognitive and emotional burden. Defending the Right to Be Fat Dr. Marianne shares a recent dream in which she found herself defending her fatness to another person. When she woke up, she realized how closely the dream reflected the experience of living in a larger body today. Fat people often have to defend their right to exist without pursuing intentional weight loss. They may have to advocate for appropriate healthcare, accessible seating, clothing, travel accommodations, and the basic right to occupy space without apology. That emotional labor takes energy. For neurodivergent people, the burden can become even greater. Autistic people and ADHDers may already expend significant energy navigating sensory needs, executive functioning, uncertainty, masking, and environments that weren't designed for neurodivergent nervous systems. When neurodivergence intersects with anti-fat bias and other forms of marginalization, the cumulative mental health toll can become significant. Internalized Weight Bias Doesn't Mean You've Failed at Recovery Eating disorder recovery happens in the real world, not in a protected bubble. You can appreciate your body and still feel hurt by weight stigma. You can reject diet culture and feel grief when plus-size clothing disappears. You can practice fat acceptance and still have moments when you wonder whether life would be easier in a smaller body. Those experiences don't erase recovery. Sometimes what looks like body dissatisfaction is actually grief, anger, exhaustion, or a desire to move through the world without constantly having to advocate for your right to belong. Dr. Marianne shares the question that helps her separate internalized weight bias from her own values: Do I actually want a different body, or do I want a different world? Related Episodes How a Part of Me Wanted to Take a Weight-Loss Drug on Apple & Spotify. My Eating Disorder Recovery Story on Apple & Spotify. Finding Liberation-Focused Eating Disorder Support If the Age of Ozempic has stirred up old body image struggles, eating disorder thoughts, or internalized weight bias, you don't have to navigate those experiences alone. Finding an eating disorder therapist or provider who understands weight stigma can make a profound difference. Liberation-focused, trauma-informed, neurodivergent-affirming eating disorder treatment can create space to examine these experiences without making weight loss the goal. If you'd like to work with Dr. Marianne, she provides eating disorder therapy in California for adolescents and adults navigating anorexia, bulimia, binge eating disorder, ARFID, body image concerns, and neurodivergence. If you live elsewhere, Dr. Marianne also offers consultations and coaching for individuals, families, and professionals. Learn more about working with Dr. Marianne at drmariannemiller.com.

The Wall Street Journal reports that major Gulf energy exporters, including countries such as Saudi Arabia and the UAE, are increasingly concluding that Iran may retain effective control over the Strait of Hormuz for the foreseeable future. While they dislike this outcome, many see it as preferable to a return to full-scale war. Axios reports that, for only the third time in U.S. history, women now hold more jobs than men in the American workforce. As of February 2026, there were about 200,000 more women employed than men, according to federal labor data highlighted by Indeed's Hiring Lab. Fortune reports that women now hold more jobs than men in the U.S. workforce for only the third time in history, but argues that the bigger story is not women entering the workforce. Instead, it's that men are increasingly leaving or not entering the labor force. Psychology Today explores a growing phenomenon sometimes called“Ozempic divorce”: reports that some marriages and long-term relationships experience strain or even break down after one partner achieves significant weight loss using GLP-1 medications such as Ozempic or Zepbound. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

The Wall Street Journal reports that major Gulf energy exporters, including countries such as Saudi Arabia and the UAE, are increasingly concluding that Iran may retain effective control over the Strait of Hormuz for the foreseeable future. While they dislike this outcome, many see it as preferable to a return to full-scale war. Axios reports that, for only the third time in U.S. history, women now hold more jobs than men in the American workforce. As of February 2026, there were about 200,000 more women employed than men, according to federal labor data highlighted by Indeed's Hiring Lab. Fortune reports that women now hold more jobs than men in the U.S. workforce for only the third time in history, but argues that the bigger story is not women entering the workforce. Instead, it's that men are increasingly leaving or not entering the labor force. Psychology Today explores a growing phenomenon sometimes called“Ozempic divorce”: reports that some marriages and long-term relationships experience strain or even break down after one partner achieves significant weight loss using GLP-1 medications such as Ozempic or Zepbound. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org

Wondering how much protein you actually need while taking Ozempic, Wegovy, Mounjaro, or Zepbound?You've probably heard over and over again that you need to "eat more protein" on a GLP-1—but how much do you really need? Do protein shakes count? Can you eat too much protein? And is it true that your body can only absorb 30 grams at a time?In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna answers the most common questions she hears from clients about protein and GLP-1 medications. You'll learn why protein is so important during weight loss, how protein supports muscle health, common myths to stop believing, and practical strategies to help you reach your protein goals—even when your appetite is low.Whether you're just starting your GLP-1 journey or you've been taking your medication for months, this episode will help you feel more confident about nourishing your body without obsessing over numbers.In this episode, you'll learn:Why protein is one of the most important nutrients while taking a GLP-1How protein helps support muscle during weight lossHow protein needs are determined—and why there isn't one perfect number for everyoneThe biggest protein myths I hear as a Registered DietitianWhether protein shakes "count"Can your body really only absorb 30 grams of protein at a time?Easy ways to increase your protein intake when your appetite is lowMy favorite high-protein foods for breakfast, lunch, dinner, and snacksThe biggest protein mistakes I see people make on GLP-1 medicationsIf you've ever searched "How much protein should I eat on Ozempic?", "How much protein do I need on Wegovy?", or "Do I need protein shakes on a GLP-1?", this episode is for you.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into the latest innovations and strategic shifts propelling the industry forward. A notable dialogue emerging in psychiatric drug development comes from TLDR Biotech's engagement with Shlomi Raz and Ken Belotsky, co-founders of Palomar Labs. This conversation heralds a transformative shift in psychiatric treatments, moving beyond traditional psychedelics toward novel approaches deeply rooted in human experience. Initially inspired by the therapeutic potential of psychedelics such as psilocybin, early research, notably from Johns Hopkins, sought to establish these compounds within a biopharmaceutical framework. Despite historical evidence supporting their efficacy, challenges persisted in reclassifying these Schedule I substances as viable therapies. Raz and Belotsky, pioneers in this initial psychedelic wave, now lead efforts at Palomar Labs to develop next-generation therapeutics targeting serotonin receptors without the hallucinogenic effects typical of classical psychedelics. This approach seeks to dismantle longstanding industry biases against specific receptor targets known as "anti-targets." A critical concept in their methodology is "neuroplastogens," as popularized by David Olson at UC Davis. These compounds are believed to induce beneficial neuroplastic changes without causing hallucinations. However, Palomar Labs exercises caution, viewing neuroplasticity not as a definitive biomarker for therapeutic efficacy but rather as one of many aspects to consider. Their unconventional "reverse" drug development model begins with anecdotal human experiences and is validated backward through preclinical animal models before advancing to clinical trials. This method relies on overlooked data sources—such as discarded trial reports and traditional medicine use cases—to uncover therapeutic candidates traditionally ignored due to biases against certain receptor targets. For example, they explore therapies for Parkinson's disease bypassing direct dopamine receptor modulation and treatments for Alzheimer's-related aggression avoiding heavily sedative antipsychotics. Palomar Labs' venture studio model emphasizes disciplined capital allocation and an unbiased approach to research outcomes. By prioritizing drug candidates with strong evidence from human experiences, they aim to swiftly advance promising therapies to proof-of-concept stages, readying them for further development by pharmaceutical partners or venture-backed entities. This paradigm shift from target-centric development to a model grounded in empirical human data represents a significant advancement in psychiatric drug discovery. In other industry news, Replimune has successfully navigated regulatory hurdles to secure FDA approval for its melanoma therapy, Tudriqev, following two prior rejections. This achievement underscores the resilience required in drug development and strategic regulatory engagement. The approval highlights the potential of oncolytic virus therapies—Tudriqev employs an innovative approach by using viruses to selectively infect cancer cells while sparing healthy tissue, simultaneously stimulating an immune response. Meanwhile, Eli Lilly continues its dominance in the obesity treatment market with Zepbound, despite new oral competitors. The enduring preference for injectable solutions highlights established efficacy and safety profiles that continue to resonate with healthcare professionals. In China, TransThera has gained regulatory approval for a bile duct cancer treatment, marking a significant step forward for Chinese innovation in oncology. Such advancements not only diversify treatment options but also elevate China's status as a pivotal contributor to global drug development. Challenges persist across the sector, exemplified by Fresenius Kabi's recall of a mislabeled morphine lot due to overdose risks. This incident underscores the vital importance of stringent quality control measures essential for patient safety. The biopharmaceutical landscape also sees Takeda securing FDA approval for its first-in-class orexin receptor agonist targeting narcolepsy—a testament to innovative approaches addressing unmet needs in sleep disorders. Amidst these developments, BioMarin has opted to terminate its $270 million rare disease asset following unsatisfactory Phase 3 results. Such decisions highlight the inherent risks within drug development pipelines and underscore the necessity for strategic flexibility. Leadership changes are shaping corporate trajectories too; BioNTech's appointment of Guido Oelkers as CEO exemplifies this trend. His experience will likely drive strategic realignments crucial for navigating complex industry challenges. Finally, the industry's focus on digital transformation is evident through Bausch + Lomb's partnership with VerilyMe—a collaboration aimed at enhancing dry eye education via digital and AI technologies. These stories collectively embody the dynamic nature of the pharmaceutical and biotech industries—where regulatory achievements, strategic pivots, and technological advancements are continuously redefining therapeutic landscapes and enhancing patient care worldwide. As we continue navigating this rapidly evolving field, staying informed on these developments is crucial for leveraging opportunities and addressing challenges within this innovative sector.Support the show

Today we learn how to lose weight with GLP-1 medications, without losing muscle mass. Our expert guest is Ron Hoyler, a Diabetes Educator, Executive healthcare and diabetes technology leader at St. Luke's Hospital System in Overland Park, Ks. Ron will explain the history of GLP-1s from the 1990s till now, and the difference between the versions for diabetes vs the versions for weight loss. You know the names: Ozempic, Wegovy, Mounjaro, and Zepbound, just a few of the powerful once-weekly injectable medications divided into two drug pairs based on their active ingredients and FDA approvals. This is season 22, Episode 23 of America's Healthcare Advocate. I'm Cary Hall. As discussed in this podcast, we are providing these additional assets to help you in your path to successful weight loss: The GLP-1 Nutrition Exercise Protein Guidelines for GLP-1 meds https://irp.cdn-website.com/9d5dbe37/files/uploaded/GLP-1_Nutrition_Exercise_Protein_Foods_and_Meal_Plan+-+%28AHA%29.pdf The new Medicare Bridge Program guide https://irp.cdn-website.com/9d5dbe37/files/uploaded/Medicare_GLP-1_Bridge_Program_Qualification_Guide+%28AHA%29+.pdf And the amazing bio and qualifications of our expert guest, Ron Hoyler https://irp.cdn-website.com/9d5dbe37/files/uploaded/AHA+-+RON+HOYLER+Bio.pdf As always, if you need help or have something to share, contact me using the form on my website and let me know what's on your mind, the issues you are dealing with, or any other health, healthcare, or health insurance questions or concerns. Visit: https://www.americashealthcareadvocate.com/contact-us

Our kidneys do an incredible job filtering our blood every hour of every day. Most of us have two kidneys, and each one has about a million microscopic filters called glomeruli. Unlike the filters in our HVAC system, though, these filters cannot be replaced. But they do their work so well and unobtrusively that most of us don't even think about our kidney function. Although 37 million Americans have kidney trouble, the majority are unaware of their situation. Two tests could reveal how well the kidneys are working. What are they, and how often should you ask about them? At The People's Pharmacy, we strive to bring you up‑to‑date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, August 8, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on August 10, 2026. What Are the Two Tests That Reveal Kidney Trouble? Chronic conditions like high blood pressure and diabetes put a strain on the kidneys. They are very common problems that signal the need for kidney function monitoring. Our guest expert, Dr. Samir Parikh, suggests that all of us should know our numbers. One is derived from the level of creatinine in the blood. This is normally part of a basic metabolic panel. Usually, the panel results will include a number for the estimated glomerular filtration rate (EGFR) calculated from the value for blood creatinine. The other crucial test is a urine test for protein. Keeping Kidneys Healthy by Staying Properly Hydrated One of the simplest tactics to keep kidneys healthy is to provide them with enough liquid. We get some fluid from the food we eat, which may be one reason eating fruits and vegetables seems to be good for us. They are full of water! We also need to drink fluid, and plain water is probably the best choice. It would be smart to use thirst as a guideline and make sure to drink when thirsty. We do avoid overdoing water consumption, though, as overloading the kidneys with more fluid than they can handle is dangerous as well. Medicines That Are Hard on the Kidneys We mentioned to Dr. Parikh the experience of an older friend, a devoted runner, who discovered that taking ibuprofen after a run reduced the likelihood of having to get up overnight to urinate. He reminded us and our listeners that nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, celecoxib or meloxicam can be hard on the kidneys. That doesn't mean we shouldn't ever take such pain relievers, but perhaps we should try not to make it a habit. When we asked about other medicines that might be tough on the kidneys, he mentioned PPIs. Proton pump inhibitors such as omeprazole (Prilosec) or esomeprazole (Nexium) are often used to treat heartburn or other digestive symptoms. Regular use can put a strain on the kidneys, although the gastroenterologist recommending the medicine might not warn you of that side effect. We asked about environmental toxins and learned that heavy metals such as lead or arsenic can harm the kidneys along with other organs. We should make sure that the food we eat and the water we drink are not contaminated with such compounds. The Possible Benefits of Vitamin B Dr. Parikh has been studying how the kidneys respond to the B vitamin nicotinamide. The preliminary work he and his colleagues have done so far is promising. However, they have not conducted clinical trials to find out whether the vitamin could help people with early kidney disease. Because kidneys work so hard, they need a lot of energy to be produced by the mitochondria in their cells. Those mitochondria need NAD+ (nicotinamide adenine dinucleotide) to function at their best. Providing additional nicotinamide appears to help (Nature Reviews. Nephrology, Feb. 2020).  One to three grams a day appears to be safe and may be beneficial. Medications That Can Promote Kidney Health Some medicines initially developed for other conditions are proving to be helpful in treating kidney disease. In particular, these include diabetes drugs known as SGLT2 inhibitors like dapagliflozin (Farxiga) or empagliflozin (Jardiance). They help slow the decline of kidney function (New England Journal of Medicine, Nov. 4, 2022). GLP-1 agonists may also be familiar because they too are used to treat diabetes. Medications such as semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound) have made headlines as weight loss and diabetes meds, but they also can reduce the risk of kidney failure and other bad outcomes (Lancet. Diabetes & Endocrinology, Jan. 2025). The benefits of these types of drugs should give us hope that we can go from slowing the progression of kidney disease to stopping it in its tracks Taking Care of Your Kidneys We asked Dr. Parikh what we should be doing to care for our kidneys and keep them healthy. He urged us once again to know our numbers: most importantly, the numbers from the two tests we discussed, blood creatinine and urine protein. Other numbers that are important for kidney are our blood pressure and, for those with diabetes, HbA1c. In addition to paying attention to all those numbers, we need to embrace a lifestyle that will help keep them where they belong. That means following a heart-healthy diet, staying physically active and getting adequate sleep. This Week’s Guest Samir M. Parikh, M.D., FASN, is Professor of Internal Medicine and Pharmacology and Chair of Internal Medicine at the University of Texas Southwestern. He holds the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy, Sr., Chair in Molecular Nephrology. Dr. Samir Parikh, University of Texas Southwestern Listen to the Podcast The podcast of this program will be available Monday, August 10, 2026, after broadcast on Aug. 8. This week's podcast has additional information on a possible role for sodium bicarbonate (baking soda) for kidney function. We also discussed medical silos, and how that leads to gastroenterologists overlooking the kidney risks from PPIs. Also, what should prospective kidney donors consider? You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

Join co-hosts Mark McNease and Rick Rose for this week's Twist take on a crazy world. We talk politics, culture, weight loss, and our weekly Twist recommendations. Quirky correspondent Prance confesses his Below Deck addiction, and Mark and Rick offer our highs and lows as America spirals. 

Market update for Thursday August 6, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode, Zaid covers:What the gold rally says about the dollar, bond yields and the FedDisney's earnings beat, powered by parks, streaming and Toy Story 5Eli Lilly's monster quarter as Mounjaro and Zepbound sales surgeDoorDash's DashPass growth and Sandisk's surprising post-earnings selloffWhy used electric vehicles are suddenly rising in value

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

P.M. Edition for Aug. 5. Seven-year-old Whatnot is gaining popularity among people drawn to its high-energy live auction sales on everything from fashion to trading cards. But as WSJ retail reporter Hanna Krueger discusses, some users say they're hooked even when they feel like they should walk away. Plus, progressive candidate Abdul El-Sayed clinched the Democratic senate nomination in a closely-watched race in Michigan. We hear from Journal reporter Terell Wright about what this means for the Democratic party's future. And Google shakes up the leadership of its AI operations as it struggles to keep pace with competitors' top models. Alex Ossola hosts. Whatnot, the Live Shopping App Where Some People Bid Until They're Broke  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Disney's third-quarter revenue was boosted by theme park visitors and Toy Story 5. And Eli Lilly posted higher revenue on continued GLP-1 demand. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to Season 7 of The Hormone Genius Podcast! We're kicking off this new season with a timely conversation about one of the most talked-about topics in medicine today: GLP-1 medications for weight loss. From Ozempic® and Wegovy® to Zepbound®, these medications have sparked excitement, controversy, and countless questions. Are they safe? Who are they for? Are they simply a shortcut, or could they be a powerful tool for improving long-term health? In this episode, Teresa breaks down the science behind GLP-1 medications, explaining how these naturally occurring hormones help regulate blood sugar, appetite, digestion, and metabolism. You'll learn how these medications were originally developed for diabetes, why they've become such a breakthrough in obesity treatment, and what the latest research tells us about their benefits beyond weight loss. Jamie guides the conversation using the B.R.A.I.N. framework, Benefits, Risks, Alternatives, Intuition, and Next Steps, to help listeners think critically and confidently when discussing treatment options with their healthcare provider. Together, we discuss: What GLP-1 medications are and how they work The difference between semaglutide (Ozempic®, Wegovy®) and tirzepatide (Zepbound®) Why obesity is now recognized as a chronic disease, not simply a lack of willpower The concept of "food noise" and how GLP-1 medications may reduce constant thoughts about food Potential benefits beyond weight loss, including improvements in diabetes, cardiovascular health, inflammation, and even emerging research on addiction Common side effects, safety concerns, and who may not be a good candidate The importance of preserving muscle mass with adequate protein intake and strength training How GLP-1 medications compare to alternatives such as lifestyle changes, metformin, and nutritional supplements Why these medications should be viewed as one tool within a comprehensive plan not a replacement for healthy habits Perhaps most importantly, this episode emphasizes the value of an individualized approach. There is no one-size-fits-all answer. The best treatment plan considers your medical history, goals, lifestyle, and values in partnership with a trusted healthcare professional. Whether you're curious about GLP-1 medications, considering them yourself, or simply want to better understand the science behind the headlines, this episode offers an evidence-based, balanced perspective to help you make informed decisions about your health. Join us as we launch Season 7 with one of the biggest conversations in modern medicine, and discover why understanding your hormones and metabolism is key to becoming your own Hormone Genius. Hormone Genius wants YOU to partner with us! PODCAST PARTNER: docs.google.com/forms/d/e/1FAIpQL…Q0iRgHqg/viewform MONTHLY SPONSOR: docs.google.com/forms/d/e/1FAIpQL…al5nkGyA/viewform BRAND PARTNER: docs.google.com/forms/d/e/1FAIpQL…d8-G5qaA/viewform Thank you to our podcast sponsors: We Heart Nutrition: 20% OFF CODE GENIUS Grazing Beauty Tallow: grazingbeauty.com 10% OFF Code HORMONEGENIUS Hormone Genius Perimenopause Program at www.hormonegenius.com Medical Disclaimer This podcast is intended for educational and informational purposes only and should not be considered medical advice. The information shared in this episode is not intended to diagnose, treat, cure, or prevent any disease. Always consult your qualified healthcare provider regarding any medical concerns or before making changes to your healthcare routine.

Andrew, Ben, and Tom discuss SpaceX falling 11% despite laying out an ambitious AI and Starlink roadmap including Grok 5 trained on internal SpaceX data by year-end, 1.4GW of current compute growing toward 10GW by end of 2027, deploying NVL72-designed data centers on the ground rather than in space, boots on the moon by 2028, and the goal of scaling launch cadence to one per day in 2027, SpaceX's decision to go exclusively with Nvidia sending AMD down 9% despite good results and CPU acceleration while Arista Networks jumped 14% on accelerating networking demand tied to Nvidia, CVS raising guidance and re-adding Zepbound to its formulary while publicly backing Eli Lilly with expanded GLP-1 support, Lilly beating on stronger-than-expected GLP-1 pricing, Disney rising 4% on parks strength and a TikTok short-form video partnership, Uber slipping despite record first-time user additions, and the JOLTS report showing softer job openings but likely not a signal Warsh will weigh.Join our live YouTube stream Monday through Friday at 8:30 AM EST:http://www.youtube.com/@TheMorningMarketBriefingPlease see disclosures:https://www.narwhal.com/disclosure

Should Christians take GLP-1 medications like Ozempic, Wegovy, Zepbound, or Mounjaro? In this episode, we're diving into a biblical perspective on these increasingly popular weight-loss medications. Rather than giving a one-size-fits-all answer, we'll explore how to seek the Holy Spirit's wisdom, discern God's direction for your health journey, and ensure that Christ—not any tool—remains at the center of your confidence, healing, and identity. What You'll Learn: Why GLP-1 medications are a tool—not a savior How to discern whether a GLP-1 is right for your unique situation The difference between quieting food noise and healing your relationship with food Common risks and limitations of GLP-1 medications Questions to prayerfully ask before making a health decision How to pursue health in a way that brings glory to God Why your confidence and identity should always be rooted in Christ Ready to heal your relationship with food with Jesus at the center? Book a FREE 30-minute call with Abbie here: https://bio.site/abbiefrye

Food noise is sneaky. It's the constant bargaining over seconds, the background craving that turns “normal portions” into a daily fight, and the quiet weight regain that can show up even after you've lost over 100 pounds. We're Stephanie and Justy, and we're sharing an honest update on why we went back on Zepbound (tirzepatide) and why, for us, “just try harder” wasn't a plan we could sustain.We break down the practical side of GLP-1 maintenance, including how we're using Lilly Direct Zepbound vials (not pens), what the prescription and refill rules look like, and how dosing from a vial gives flexibility but also demands responsibility. We also talk about why we're more comfortable with regulated, name-brand medication than with unregulated compounded versions, even while respecting that different people make different choices.Then we get into what life feels like on a maintenance dose: being full after a few bites, forgetting to eat unless we set an alarm, turning down dessert without feeling deprived, and watching restaurant portions suddenly look unreal. We share the dosing experiments we tried, how end-of-week hunger shows up, and the side effects we still notice like nausea with too much sugar or alcohol, constipation management, and occasional lightheadedness that may be tied to low blood pressure or not eating enough.We also make the bigger point we wish more people would say out loud: if obesity is a chronic disease, treatment may need long-term support. We talk about nutrition counseling, protein goals, vitamins, blood work, and why “lose 20 pounds and quit” can backfire if you don't use the time to build habits. If you're navigating Zepbound, GLP-1 medications, weight loss maintenance, or bariatric aftercare, hit play, then subscribe, share this with a friend, and leave a review so more people can find real-world guidance.Follow Justy & Steph on Instagram, where they share their weight loss journey and road to living a happy & healthy lifestyle.@we.are.losing.it If you prefer video to see us talk through our topics, you can watch us on YouTube. https://youtube.com/@wearelosingitShow your support by hitting download, like & subscribe! We truly appreciate each and every one of you!!

On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com   Transcript:  (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you're organizing: a fundraiser, walk, or local meetup Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It's your chance to share what you're doing and help others get connected! Full instructions are on the website. While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921.   Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip:   Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter" https://www.youtube.com/watch?v=nnSQS43Eil8   Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet." Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer:   XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time.   The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values.   The device needs further validation in diverse clinical settings and across large diabetic cohorts.   https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx   XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level < 3.9 mmol/L (70 mg/dL). The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C.   https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared.   The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal.   https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox..   XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years. These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women) Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems. And while the study says it's 37% higher for the younger group, the actual rate was still very low. As always, I'll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2.   https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir XX Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life. https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx XX Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year. https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/ XX The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program. Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes. The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress. The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions. https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/ XX Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump. Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott's dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year. Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month. https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/ XX Eli Lilly expands it's partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply XX Alex Cooper – the host of the top podcast Call her Daddy – announced she's been diagnosed with gestational diabetes.   "When I got this diagnosis, the first couple days, I was really hard on myself," the 31-year-old admitted. "It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it's me on an island." She says she found an online community that's been helping. In sharing her experience, she hoped it would alleviate the stress. https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis XX Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes. Check out all the charities and vote for your favorites – you've heard of so many of these I promise – at the link in the episode show notes, . https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact

Gray divorce after 50 can affect your health, strength, bone density, muscle, and independence. Learn practical ways to rebuild stronger.When we talk about gray divorce, we usually talk about the house, retirement accounts, Social Security, spousal maintenance, and the fear of beginning again. But we do not talk nearly enough about the body carrying us through it all.In this solo episode of Doing Divorce Different, Lesa Koski shares why physical strength deserves a place in every woman's gray divorce plan. Drawing from her own breast cancer recovery, osteopenia diagnosis, menopause journey, and experience with OsteoStrong, Lesa explores how small, sustainable choices can help women care for their bones, preserve muscle, support balance, and protect their independence.You'll hear a thoughtful discussion about bone-density screening, strength and weight-bearing exercise, nourishment during stressful seasons, and questions to ask your healthcare provider—especially if you are postmenopausal, have cancer-treatment history, or use a GLP-1 medication such as Ozempic, Wegovy, or Zepbound.Gray divorce can make the future feel uncertain, but caring for your body is one place where you can begin reclaiming agency. You do not have to transform everything at once. One walk, one nourishing meal, one appointment, or one conversation can become the next strong step in your comeback.This episode is for educational purposes only and is not medical advice. Consult your physician or another qualified healthcare professional about your personal health, medications, nutrition, exercise, and bone-density screening.If this episode encourages you, please follow the show, save it for later, and share it with a woman navigating gray divorce, menopause, weight loss, cancer recovery, or another major midlife transition.Timestamps (approximate):(00:00) Why physical strength matters during gray divorce(02:35) Bone loss, osteopenia, and the hidden risk to independence(05:10) Reclaiming agency through small, healthy choices(07:45) Lesa's breast cancer recovery and bone-health wake-up call(11:05) Lesa and her mother's personal experience with OsteoStrong(15:35) Bone-density screening, DEXA scans, and questions for your doctor(19:10) How divorce stress can disrupt sleep, food, and exercise(22:30) GLP-1 weight loss, muscle loss, and bone-health conversations(27:10) Five ways to support strength, mobility, and independence(33:20) Why nourishment and community belong in your comeback plan(37:40) Choosing one strong next step after divorceKey Takeaways:Physical strength supports mobility, balance, confidence, and independence during and after gray divorce.Bone loss can be silent, so women should ask a qualified healthcare provider whether bone-density screening is appropriate for them.Small, repeatable actions—walking, resistance training, nourishing meals, rest, and medical appointments—can restore a sense of agency.Women experiencing significant weight loss, including those using GLP-1 medications, should discuss muscle, nutrition, and bone health with their healthcare providers.Community is part of strength; supportive groups, friends, faith communities, and wellness spaces can help women feel seen during major transitions.Guest Bio:This is a solo episode featuring Lesa Koski, a divorce mediator, divorce coach, attorney, educator, author, breast cancer survivor, and host of Doing Divorce Different. Lesa helps women approach divorce with clarity, dignity, and hope while creating a strong, meaningful life on the other side. Her guiding message is: Midlife is not your crisis—it's your comeback.Resource Links:Explore OsteoStrong Minnesota through Lesa's affiliate link: https://osteostrongmn.com/affiliate-referral-koski/Learn about Soberlink for divorce and family law through Lesa's affiliate link: https://www.soberlink.com/divorce/family-law?utm_source=affiliatelink&utm_medium=referral&utm_campaign=lesa-koski-affiliatelinkLearn more about Lesa, divorce coaching, mediation, and her community: https://lesakoski.comAffiliate disclosure: Lesa may receive compensation if you use an affiliate link. This does not increase your cost. OsteoStrong is not medical treatment, and individual experiences vary. Consult an appropriate healthcare professional before beginning a new health or exercise program.Tags/Keywords:gray divorce, gray divorce after 50, divorce after 50, women and divorce, bone health for women, bone density after menopause, osteopenia, osteoporosis prevention, strength training after 50, menopause bone health, GLP-1 muscle loss, GLP-1 bone health, Ozempic and bone health, Wegovy and muscle loss, Zepbound and strength training, women over 50 health, midlife comeback, divorce recovery, rebuilding after divorce, healthy aging for women, independence after divorce, Doing Divorce Different, Lesa Koski, divorce coach, divorce mediator, OsteoStrong Minnesota

Are you tired of working out endlessly and trying every generic diet, only to see zero results? What if the problem isn't your discipline, but a lack of information about your unique biology? In this episode of The Level Up Podcast, Paul Alex sits down with Dora Maria, a Bay Area native, UC Berkeley graduate, and former healthcare executive who spent 15 years within the medical system. Dora shares her incredible journey from growing up in a garage while her mother battled breast cancer, to reaching the peak of her career, only to find herself in the back of an ambulance at 39 years old. After struggling with pre-diabetes, a 50-pound weight gain, and uncontrolled hypertension, Dora realized that the traditional healthcare system is designed for surviving, not thriving. She took her health into her own hands, utilizing DNA testing and advanced lab panels to uncover exactly what her body needed. Dora breaks down the truth about popular weight loss trends, explaining why the Keto diet landed her in the ER with appendicitis, and why high-intensity workouts like Orange Theory were actually causing her body to hold onto fat. She also dives deep into the world of peptides, explaining the difference between weight loss GLPs (like Ozempic and Zepbound) and powerful longevity peptides (like BPC-157 and the Wolverine stack) for tissue regeneration and anti-aging. If you are a high-performing professional or entrepreneur looking to optimize your health, buy back your time, and finally get a customized plan that fits your DNA, this episode is a game-changer! Make sure to follow Dora on Instagram: @iamdoramaria Listen to The Level Up Podcast w/ Paul Alex: Available on Apple Podcasts and Spotify. Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you wondering if GLP-1 medications like Ozempic or Zepbound are right for you? In this episode of FAT LOSS SCHOOL, we're opening the classroom doors for GLP-1 School— practical, science-based lessons designed specifically for women over 50. GLP-1 medications have changed the conversation around weight loss, but they aren't magic. They are simply one tool. Whether you're already taking a GLP-1, considering one, or know someone who is, understanding how to protect your muscle, metabolism, and long-term health is essential. As a certified FASTer Way coach who has completed specialized training in GLP-1s and metabolic health, I'll explain what these medications do, what they don't do, and how to build healthy habits that support lasting fat loss. In This Episode You'll Learn: What GLP-1 medications are and how they work How GLP-1s reduce appetite and support weight loss The difference between weight loss and fat loss Why preserving muscle is critical after age 50 How much protein women should prioritize while taking a GLP-1 Why strength training becomes even more important during GLP-1 treatment The importance of hydration, fiber, and nutrient-dense foods How to avoid losing muscle along with body fat Why healthy habits are still the foundation of long-term success How the FASTer Way complements GLP-1 medications with nutrition, fitness, and accountability Key Takeaway GLP-1 medications can be incredibly helpful tools for the right person—but they work best when paired with healthy lifestyle habits. If your goal is to lose fat while protecting muscle, you'll need: Adequate protein Regular strength training Daily movement Proper hydration Quality sleep Consistent nutrition Ongoing coaching and accountability The medication may reduce your appetite, but your daily choices determine the quality of the weight you lose. Ready to Learn the FASTer Way? Whether you're using a GLP-1 medication, thinking about one, or simply want a sustainable approach to fat loss after 50, I'd love to coach you. Inside my FASTer Way to Fat Loss® program, you'll learn how to: Preserve lean muscle Improve metabolic health Build strength Prioritize protein Develop lifelong nutrition habits Create sustainable routines that continue working long after any medication ends Here is the link to join my next class for women over 50: https://www.fasterway.com/?aid=AMYBRYAN  Connect with Amy Join my free Facebook community for women over 50, subscribe to my newsletter, email me, schedule a discovery call, or grab a freebie here:  www.linktr.ee/amybryanfasterway If today's episode helped you better understand GLP-1 medications, please leave a review and share this episode with a friend who could benefit from this information.

Can you drink alcohol while taking Ozempic, Wegovy, Mounjaro, or Zepbound?If you've been wondering whether it's safe to enjoy a glass of wine, a cocktail on vacation, or a drink at a wedding while taking a GLP-1 medication, you're not alone. This is one of the most common questions I get as a Registered Dietitian.The good news? For many people, alcohol doesn't have to be completely off-limits. But your body may respond differently than it did before starting your medication.In this episode, I'm breaking down the science behind alcohol and GLP-1 medications, why your tolerance may have changed, the risks to be aware of, and practical tips to help you make informed decisions without fear or guilt.Because living a healthy lifestyle isn't about following rigid rules—it's about understanding your body and making choices that support your goals.In this episode, we'll cover:Can you safely drink alcohol while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Why alcohol may affect you differently after starting a GLP-1The latest research on GLP-1 medications and alcohol cravingsWhy dehydration and nausea deserve extra attentionHow alcohol can impact reflux and blood sugarWhat counts as one standard drinkShould you skip your GLP-1 injection if you're planning to drink?Practical tips for drinking more safely while taking a GLP-1When alcohol may not be the best choice and when to talk with your healthcare providerWhether you're planning a vacation, heading to a birthday party, or simply wondering if your Friday night glass of wine still fits into your lifestyle, this episode will help you navigate alcohol with confidence while staying focused on your long-term health.

Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides? This week on "The Top Line," Fierce's Zoey Becker, Will Maddox and Kevin Dunleavy chat about some of the biggest recent stories. From a psychedelics acquisition that could spark more movement in the emerging field to an advisory committee meeting on peptides shrouded in political controversy to a lawsuit between the two major obesity drugmakers, we’ll catch you up on the latest developments shaking up the biopharma world. To learn more about the topics in this episode: ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads Novo escalates Lilly false advertising suit with planned bid to halt comparative ads See omnystudio.com/listener for privacy information.

The Cutting Edge #26 Are you currently taking a GLP-1 medication (like Ozempic, Wegovy, Mounjaro, or Zepbound) and planning for plastic surgery or general anesthesia? In this critical episode of The Cutting Edge Podcast, host Mel sits down with bariatric therapist Ashlyn Douglass-Barnes and board-certified plastic surgeon Dr. Omar Beidas to unpack the medical, psychological, and surgical risks every patient must know. If you are navigating weight loss surgery, post-bariatric skin removal, or GLP-1 therapy, this video explains why stopping your injection before surgery isn't optional—it could literally save your life.

In this replay episode, we interview obesity medicine specialist Dr. Alexandra Sowa, author of The Ozempic Revolution. The discussion demystifies GLP-1 medications such as Ozempic, Wegovy, semaglutide, and tirzepatide, explaining how they work, who they are designed for, and why they represent a major shift in the treatment of obesity and metabolic disease. Dr. Sowa emphasizes that obesity is not a failure of willpower, but a complex chronic disease driven by genetics, hormones, metabolism, and environmental factors.  Our discussion moves beyond the basics of GLP-1 medications like Ozempic, Wegovy, Zepbound, and semaglutide to explore practical questions many patients have: *How much do these medications cost? * Will insurance cover them? * What are the side effects? * How long do you need to stay on treatment? * And what lifestyle changes are essential for lasting success? Dr. Sowa explains that GLP-1 medications are powerful tool, but they are not a magic solution. Sustainable weight loss and improved metabolic health require proper nutrition, strength training, medical supervision, and a long-term commitment to healthy habits. Show Notes/Links: www.hotflashescooltopics.com JOIN THE HOT FLASHES & COOL TOPICS PODCAST COMMUNITY: Website: www.hotflashescooltopics.com Newsletter: Link Mail:  hotflashescooltopics@gmail.com Instagram https://www.instagram.com/hotflashesandcooltopics Facebook : www.facebook.com/hotflashescooltopics YouTube https://www.youtube.com/@HotFlashesCoolTopics  

Can a GLP-1 medication like Zepbound help you break through severe bariatric weight regain years after surgery? In this episode of the Our Sleeved Life Podcast, host Mel celebrates her 11years bariatric anniversary by sitting down with Jenny Espino (@jennyloseswithzep). After undergoing gastric bypass surgery 20 years ago, Jenny lost 112lbs built a family, and welcomed four boys. But after a debilitating back injury and COVID-19 lockdowns, she found herself back in her 270lbs . Discover how Jenny utilized Zepbound (tirzepatide) to lose 25 lbs, rebuild her metabolism, and step confidently into maintenance!

July is the Saturday of summer. Life feels a little lighter, the rules feel looser, and for a minute, you can breathe before August shows up with its deadlines, resets, and Sunday scaries.As I'm getting ready for my birthday trip and trying to soak up the last bit of that July freedom, I've been thinking about how often two things can be true at the same time. I can love the life I've worked so hard to build and still feel overwhelmed. I can be proud of how far I've come in my weight and body image journey and still have days when it feels hard. I can appreciate my body and still want change.In this episode, we're talking about letting go of the all-or-nothing thinking that tells us we have to pick one truth, and making room for the messy, complicated reality of healing, growth, and actually living your life.Irresistible Links:Show Notes

Everyone's talking about Ozempic. But almost no one tells you what it's quietly doing to your body, or how to use it without paying for it later.Justin Roethlingshoefer breaks down the long-term side effects of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound (semaglutide and tirzepatide): the muscle and bone you lose, why people quit, what happens when you stop, and the protocol to do it right.This episode isn't anti-GLP-1. For type 2 diabetes, severe obesity, or high cardiovascular risk these drugs can be extraordinary. But in the STEP 1 trial, 40% of the weight lost was lean body mass: for every 10 pounds gone, up to 4 can be muscle.In this episode:

Traveling while taking Ozempic, Wegovy, Mounjaro, or Zepbound? Wondering how to enjoy your vacation without feeling like you're undoing all of your progress?The good news is—you don't have to choose between making memories and staying on track.In this episode, Registered Dietitian, Certified Personal Trainer, Gianna shares her practical, flexible approach to traveling on a GLP-1. From airports and road trips to cruises, all-inclusive resorts, and family vacations, you'll learn how to confidently navigate food, movement, hydration, and your medication—without guilt or perfectionism.Because the goal isn't to have the "perfect" vacation. The goal is to enjoy your trip, take care of yourself, and come home ready to jump back into your routine.In this episode, you'll learn:How to prepare for travel while taking a GLP-1Tips for flying with Ozempic, Wegovy, Mounjaro, or ZepboundEasy, protein-rich travel snacks to packHow to eat at buffets, restaurants, and on vacation without overthinking itWhy movement doesn't have to look like a gym workout while travelingWhat to do if the scale is higher after vacationHow to get back into your routine without guilt, detoxes, or "starting over"Why flexibility is one of the most important skills for long-term successIf you've ever worried about gaining weight on vacation or wondered how to travel while taking a GLP-1 medication, this episode is full of practical strategies you can use on your very next trip.

Ten pounds in two weeks. No hunger. No craving for coffee or alcohol. This is Jeff's personal, week-by-week account of starting tirzepatide (sold as Zepbound), tracked through blood sugar, cholesterol markers, and a noticeable dimming of everyday motivation and joy. What changed in the first two weeks: appetite, weight, and energy Tracking glucose, LDL, ApoB, and other metabolic markers with a CGM and blood panels Why alcohol and coffee stopped feeling rewarding The emerging link between GLP-1s, dopamine, and the brain's reward circuitry The trade-off between appetite control and a sense of vitality or spark This episode is for anyone weighing GLP-1s for themselves, or curious what the drugs are actually like beyond the headlines. This episode was made possible by: CocoaVia:. Use code COMMUNE2026 for 25% off at CocoaVia.com LMNT: Get a free 8-count Sample Pack of LMNT's most popular drink mix flavors with any purchase at ⁠⁠drinklmnt.com/commune⁠⁠. Stemregen: Get 20% off your first order at stemregen.co/commune with the code COMMUNEPOD Vivobarefoot: Try Vivobarefoot risk-free with a 100-day return guarantee, and get 25% off your order at ⁠⁠vivobarefoot.com/commune⁠⁠. Stripes: Visit stripesbeauty.com and use the code COMMUNE20 for 20% off our entire product line.

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are everywhere, but are they dangerous shortcuts, life-changing tools, or both?   In this episode of The Body Wisdom Podcast, Jamie Belz, FNTP, MHC, and nutrition expert Kelly Dorfman examine both sides of the GLP-1 debate, including the risks, benefits, and unanswered questions surrounding semaglutide, tirzepatide, weight loss, blood sugar, food noise, and metabolic health.   Kelly Dorfman, M.S., L.D.N., is a leading expert in using therapeutic nutrition to support brain function, energy, and mood. She has appeared on CNN's American Morning and in The Wall Street Journal, O, The Oprah Magazine, and Goop. Her award-winning book, Cure Your Child with Food: The Hidden Connections Between Nutrition and Childhood Ailments, was praised by Publishers Weekly for its "fascinating and potentially life-changing advice."   GLP-1 medications are criticized as an easy button for weight loss. They can cause nausea, vomiting, constipation, dehydration, nutrient deficiencies, muscle loss, bone loss, and other serious side effects. Questions remain about their long-term effects, what happens when someone stops taking them, and whether users may need them for life.   At the same time, GLP-1s are life-changing for some people. They may help those who have spent years battling obesity, insulin resistance, constant hunger, food noise, or a body that will not respond despite consistent effort. These medications may quiet obsessive thoughts about food, reduce overeating, improve metabolic markers, and remove shame from a struggle not always solved by discipline.   So, are GLP-1s really that bad? Or have both sides become too absolute?   Jamie and Kelly explore: • How Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, and tirzepatide differ • Why appetite, food noise, overeating, and weight are not simply matters of willpower • How GLP-1s affect digestion, blood sugar, inflammation, and reward pathways • Why rapid weight loss can mean losing muscle, collagen, and essential nutrients • The benefits of reducing overeating and improving metabolic health • The risks of digestive problems, dehydration, nutrient deficiencies, and diminished desire • Why protein, fiber, hydration, nutrients, and professional support matter • Whether GLP-1s are temporary tools or lifelong commitments • What may happen when someone stops taking a GLP-1 • How GLP-1s may affect alcohol cravings and other compulsive behaviors • Why foundational health habits still matter • How to make an informed, bio-individual decision without shame, hype, or fear   GLP-1 medications are neither all good nor all bad. For the wrong person, they may create more problems than they solve. For the right person, with the right dose and support, they may be genuinely life-changing.   Jamie encourages listeners to give the Foundations of Health an honest try and seek individualized guidance from a Nutritional Therapy Practitioner.   This episode is for educational purposes only and is not medical advice.   Other Episodes Mentioned: ⁠S2E5 (about protein)⁠ ⁠S1E7 Dehydration Nation⁠ ⁠S1E35 (on childhood obesity)⁠ Find Kelly Dorfman Online at ⁠www.kellydorfman.com⁠. Get Kelly's book:⁠ Cure Your Child with Food: The Hidden Connection Between Nutrition and Childhood Ailments ⁠ Connect with Jamie on Instagram:  ⁠⁠https://www.instagram.com/jamiebelzfntp/⁠⁠⁠⁠ ⁠⁠https://www.instagram.com/stories/thebodywisdompodcast/⁠⁠ Work with a Nutritional Therapy Practitioner (NTP): ⁠⁠NTP in Private Practice⁠⁠ ⁠⁠NTP at NTA Health ⁠⁠  Check out the ⁠Nutritional Therapy Association ⁠⁠⁠ ⁠Join a webinar to see if the Nutritional Therapy Practitioner Program is right for you!⁠ ⁠⁠⁠ Please give The Body Wisdom Podcast a five-star review and share this episode with a friend. THANK YOU!

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode, we break down Novo Nordisk's lawsuit accusing Eli Lilly of misleading patients through advertisements comparing Zepbound and Mounjaro with Wegovy and Ozempic. The fight is not simply about which medication produces more weight loss. It is about who controls the information patients receive, which evidence gets highlighted, and what gets left in the fine print.Then we examine STAT News' investigation into LifeMD, a major telehealth company promoted by Novo as a legitimate pathway to GLP-1 treatment. Former employees alleged providers were pushed to process patients at breakneck speed, sometimes reviewing as many as 25 cases per hour, while refill queues, dose increases and patient messages piled up. LifeMD strongly disputes those allegations.But this cannot become another simplistic story about telehealth being bad.More than 100 million Americans are living with obesity, and only a small number of clinicians have dedicated obesity medicine expertise. The traditional healthcare system does not have enough specialists, appointment slots or geographic reach to provide every patient with an ideal, hour-long consultation.So how altruistic can we afford to be about access?Can we demand a perfect standard of care that most patients will never be able to reach? Or does scaling treatment too aggressively risk turning patients into transactions inside a prescription machine?Access cannot become a shield for negligence. But perfection cannot become another form of gatekeeping.The patient is being fought over. This episode asks what it would actually mean to fight for them.Learn more and follow On The Pen: https://www.otplinks.comThis episode is sponsored by VoaFit, where I receive care for obesity and metabolic health. https://www.voafit.com/otp to learn more!

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week, we take a look at a couple of acronyms that are soaring in popularity and ask what their widespread adoption means for mental health. Maggie Harrison Dupré of Futurism has been following the AI space closely and has an update on lawsuits related to chatbots' culpability in numerous cases of attempted and completed suicides. She also explains some recent research about why prolonged engagement with the sycophantic computer programs can lead to spiraling out of reality. Then we're joined by Dr. Thomas Rutledge for a look at drugs like Ozempic and Zepbound. While the drugs are so new that research is slim, some psychological issues can emerge, especially related to self image and identity. He asks if food cravings and thinking about food have occupied a lot of space in your mind for years, what happens when that goes away? It's a complicated world we live in, Depresh Mode is here to help you make more sense of it. Articles by Maggie Harrison Dupré:Lawsuit: Bipolar Man Attempted Suicide After ChatGPT Poured Gasoline on His Religious DelusionsNew Paper Proposes What Really Causes AI PsychosisThese Logs of ChatGPT Allegedly Driving a Suicidal Woman to Her Death Are Deeply Disturbing Article by Thomas Rutledge:Your Brain on GLP-1s: What We're Learning About the Mental Side Thank you to all our listeners who support the show as monthly members of Maximum Fun. Check out our I'm Glad You're Here and Depresh Mode merchandise at the brand new merch website MaxFunStore.com! Hey, remember, you're part of Depresh Mode and we want to hear what you want to hear about. What guests and issues would you like to have covered in a future episode? Write us at depreshmode@maximumfun.org. Depresh Mode is on BlueSky, Instagram, Substack, and you can join our Preshies Facebook group.  Help is available right away. The National Suicide Prevention Lifeline: 988 or 1-800-273-8255, 1-800-273-TALK Crisis Text Line: Text HOME to 741741. International suicide hotline numbers available here: https://www.opencounseling.com/suicide-hotlines Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joindepresh

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

She helped spark one of the biggest health conversations of the last few years—but according to Dr. Tyna Moore, the internet completely lost the plot. The naturopathic and chiropractic doctor, metabolic health expert, and host of The Dr. Tyna Show joins us to unpack what she originally meant by "microdosing" GLP-1 medications, why severe side effects may be a sign that a dose isn't right for you, and how a nuanced conversation turned into a billion-dollar industry. Emese also shares her own experience taking Zepbound, leading to an honest discussion about whether GLP-1s are forever, who may benefit from them, and why lifestyle changes still matter. Plus, Dr. Tyna explains why your metabolism probably isn't broken, the lab markers she looks at first, how chronic stress changes your body, and why strength training is non-negotiable for women as we age. If you've ever wondered whether GLP-1s are right for you—or felt confused by the endless noise online—this episode brings the conversation back to center. A Sony Music Entertainment production.  Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts  To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Mentioned in the Episode: Learn more about your ad choices. Visit podcastchoices.com/adchoices

Recent studies say that somewhere between 12 and 16 percent of Americans have used GLP-1s like Ozempic, Wegovy, or Zepbound. Many people who take these drugs report that the meds have fundamentally changed their relationship to food. Jason Diamond is a writer who covers food, men's fashion, and culture. Throughout his life he's had a complicated relationship with both food and medication, which played a big role in how he thought about whether or not, as a new dad, to start taking GLP-1s.  Jason's story in New York Magazine is “Eating With My Daughter and My Zepbound.” The Sporkful production team includes Dan Pashman, Emma Morgenstern, Andres O'Hara, Kameel Stanley, and Jared O'Connell. Right now, Sporkful listeners can get three months free of the SiriusXM app by going to siriusxm.com/sporkful. Get all your favorite podcasts, more than 200 ad-free music channels curated by genre and era, and live sports coverage with the SiriusXM app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.